Morgan J, Richards P, Ward S, Francis M, Lawrence G, Collins K, Reed M & Wyld L (2015) Case mix does not fully explain variation in rates of non-surgical treatment of older women with operable breast cancer. FUTURE ONCOLOGY, 11(4), 14-14.
Zechmeister I, Ara R, Ward S & Stollenwerk B (2011) Have statins met our expectations? A comparison of expected health gains from statins with epidemiological trends in Austria. Journal of Public Health, 1-9.
Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W & Payne N (2007) A systematic review and economic evaluation of statins for the prevention of coronary events.. Health Technol Assess, 11(14), 1-iv.
Ward S, Simpson E, Davis S, Hind D, Rees A & Wilkinson A (2007) Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.. Health Technol Assess, 11(40), 1-144.
Ward S, Kaltenthaler E, Cowan J & Brewer N (2003) Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.. Health Technol Assess, 7(32), 1-93. View this article in WRRO
Ward S, Morris E, Bansback N, Calvert N, Crellin A, Forman D, Larvin M & Radstone D (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.. Health Technol Assess, 5(24), 1-70. View this article in WRRO
Ebrahim S, Davey Smith G, McCabe C, Payne N, Pickin M, Sheldon TA, Lampe F, Sampson F, Ward S & Wannamethee G (1999) What role for statins? A review and economic model.. Health technology assessment (Winchester, England), 3(19).
Ebrahim S, Smith GD, McCabe C, Payne N, Pickin M, Sheldon TA, Lampe F, Sampson F, Ward S & Wannamthee G (1998) Cholesterol and coronary heart disease: screening and treatment. QUAL HEALTH CARE, 7(4), 232-239. View this article in WRRO
Richards P, Ward S, Morgan J, Francis M, Collins K, Burton M, Nettleship A, Lifford K, Reed M & Wyld L (2015) Bridging The Age Gap in Breast Cancer - improving treatment decisions for older women using routine data. EUROPEAN JOURNAL OF CANCER CARE, Vol. 24 (pp 62-62)
Morgan J, Richards P, Ward S, Lawrence G, Francis M, Collins K, Reed M & Wyld L (2015) The effect of dementia on the treatment of older women with breast cancer in England. FUTURE ONCOLOGY, Vol. 11(4) (pp 13-13)
Richards P, Ward S, Morgan J, Francis M, Lawrence G & Wyld L (2015) Age, and not comorbidity, is associated with adjuvant chemotherapy use in older breast cancer patients in England. FUTURE ONCOLOGY, Vol. 11(4) (pp 20-21)
Rafia R, Ward SE, Scope A & Wyld L (2013) EVALUATING THE COST EFFECTIVENESS OF GENE EXPRESSION PROFILING AND IMMUNOHISTOCHEMISTRY TESTS. VALUE IN HEALTH, Vol. 16(7) (pp A413-A413)
Nagy B, Gray L & Ward SE (2012) COST-EFFECTIVENESS ANALYSIS OF THREE YEAR VERSUS ONE YEAR IMATINIB FOR THE TREATMENT OF PATIENTS AT HIGH RISK OF DISEASE RECURRENCE FOLLOWING SURGICAL RESECTION OF KIT (CD117) POSITIVE GASTROINTESTINAL STROMAL TUMOURS (GIST). ANNALS OF ONCOLOGY, Vol. 23 (pp 235-236)
Hummel S, Snowden J, Nield A, McGoldrick R, Harrison S, Swanborough F, Davis J, Goddard Y, Ward S, Ezaydi Y, Morley N, Downes T, Wright J & Dalley C (2012) Predicting increases in bed capacity for haematopoietic stem cell transplantation or intensive chemotherapy through simulation modelling of ambulatory care. BONE MARROW TRANSPLANTATION, Vol. 47 (pp S278-S278)
Peasgood T, Ward SE & Brazier J (2011) HEALTH STATE UTILITY VALUES IN BREAST CANCER: A REVIEW AND META-ANALYSIS. VALUE IN HEALTH, Vol. 14(7) (pp A462-A462)
Meng Y, Ward SE, Cooper K, Harnan SE & Wyld L (2011) THE POTENTIAL ROLE OF MAGNETIC RESONANCE IMAGING (MRI) IN AXILLARY NODE ASSESSMENT OF EARLY BREAST CANCER: AN ECONOMIC EVALUATION. VALUE IN HEALTH, Vol. 14(7) (pp A253-A253)
Meng Y, Ward S, Cooper K, Harnan S & Wyld L (2010) Cost-effectiveness assessment of pet and mri for the evaluation of axillary lymphnode metastases in breast cancer: A discrete event simulation model. Proceedings of the 2010 Operational Research Society Simulation Workshop, SW 2010 (pp 49-58)
Jewitt K, Pilgrim H & Ward S (2008) A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 141 (pp 38-38)
Pilgrim H, Jewitt K & Ward S (2007) A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib.. BLOOD, Vol. 110(11) (pp 376B-376B)
Bansback N, Ara R, Ward S, Anis A & Choi H (2006) Using economic methods to efficiently design clinical trials: A case study of statin therapy in patients with rheumatoid arthritis.. ARTHRITIS AND RHEUMATISM, Vol. 54(9) (pp S534-S535)
Bansback N, Ara R, Ward S, Anis A & Choi H (2006) Statin therapy for patients with rheumatoid arthritis: A cost effectiveness analysis. ANNALS OF THE RHEUMATIC DISEASES, Vol. 65 (pp 98-98)
Brennan A, Ward S & Hummel S (2002) Costing the impact of the cancer service guidance. Journal of Clinical Excellence, Vol. 4(1 SUPPL.) (pp 209-210)